title: The effects of dietary supplementation with fish oil on renal function and the course of early postoperative rejection episodes in cyclosporine-treated renal transplant recipients.
abstract: In a randomized prospective coconut oil (daily 6g[63% C8:0 and 36% C10:0] [EPA-] [n = 48])-controlled trial, we investigated the effect of a one-month dietary supplementation with daily 6 g fish oil (30% C20:5 omega-3 and 20% C22:6 omega-3 as their methyl esthers [EPA+] [n = 40]) on the incidence and course of early postoperative rejection in 88 first cadaveric, cyclosporine-treated renal transplant recipients. At one month there were no differences in renal function and incidence of rejection episodes. When analyzed separately for rejection (re+) or nonrejection (re-), the rejecting and fish oil-treated patients showed a significant better recovery of renal function after a histologically confirmed rejection episode, creatinine clearance being 43 ml/min/1.73m2 in the EPA+re+group versus 27 ml/min/1.73 m2 in the EPA-re+group (P less than 0.05), and serum creatinine being 183 and 283 mumol/l (P less than 0.05), respectively. The prerejection renal function and the decline of renal function during the rejection episode did not differ significantly between the EPA+re+ and the EPA-re+ groups. The nonrejecting fish oil-treated patients showed no better renal function than the nonrejecting coconut oil-treated patients. However, cyclosporine trough levels were significantly higher in the fish oil-treated group (EPA+re- 251 versus EPA-re- 200 ng/ml [P less than 0.05]). From these results we conclude that dietary supplements with fish oil favorably influence renal function in the recovery phase following a rejection episode in cyclosporine-treated renal transplant recipients. We further conclude that one month after grafting there is no difference in the incidence of rejection episodes between the fish- and coconut oil-treated patients. The same holds true for renal function in the absence of rejection, and for the decline in renal function during a rejection episode.
authors.affiliation: Department of Internal Medicine, University Hospital Groningen, Amsterdam, The Netherlands.
authors.forename: J J
authors.initials: JJ
authors.lastname: Homan van der Heide
authors.forename: H J
authors.initials: HJ
authors.lastname: Bilo
authors.forename: A J
authors.initials: AJ
authors.lastname: Donker
authors.forename: J M
authors.initials: JM
authors.lastname: Wilmink
authors.forename: W J
authors.initials: WJ
authors.lastname: Sluiter
authors.forename: A M
authors.initials: AM
authors.lastname: Tegzess
mesh_terms: D003404:Creatinine / Q000378:metabolism; D016572:Cyclosporine / Q000008:administration & dosage; D004032:Diet; D004311:Double-Blind Method; D005260:Female; D005395:Fish Oils; D006084:Graft Rejection; D006648:Histocompatibility; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007668:Kidney / Q000502:physiology*; D016030:Kidney Transplantation / Q000379:methods*; D008297:Male; D011446:Prospective Studies; D014508:Urea / Q000378:metabolism
chemical_list: D005395:Fish Oils; D016572:Cyclosporine; D014508:Urea; D003404:Creatinine